You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ibrutinib monotherapy

Showing 1 - 25 of 3,731
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Chronic Lymphoid Leukemia Trial in Worldwide (Ibrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Chronic Lymphoid Leukemia
  • Ibrutinib
  • +2 more
  • Graz, Austria
  • +180 more
Jan 21, 2022

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Phoenix, Arizona
  • +10 more
Feb 1, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia Trial in Switzerland (Ibrutinib,

Active, not recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • +2 more
  • Aarau, Switzerland
  • +10 more
Mar 10, 2022

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)

Active, not recruiting
Has Results
  • Lymphoma
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Gilbert, Arizona
  • +53 more
Jan 25, 2022

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
  • PCNSL
  • Milan, Italy
    Ospedale San Raffaele
Mar 13, 2023

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Trial in United States (JCAR017 (lisocabtagene maraleucel),

Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic
  • JCAR017 (lisocabtagene maraleucel)
  • +2 more
  • Birmingham, Alabama
  • +63 more
Nov 21, 2022

Mantle Cell Lymphoma Trial in Beijing

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Hongmei Third Jing
    Jun 20, 2022

    Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

    Completed
    • Chronic Lymphocytic Leukemia
    • BNC105P
    • Ibrutinib
    • Lebanon, New Hampshire
      Dartmouth-Hitchcock Medical Center
    Jan 3, 2023

    Ibrutinib Combined With Bendamustine and Rituximab in Newly

    Recruiting
    • Mantle Cell Lymphoma (MCL)
      • Beijing, Beijing, China
        Peking University Third Hospital
      May 31, 2022

      Mantle Cell Lymphoma (MCL) Trial in Japan (Ibrutinib, Venetoclax)

      Active, not recruiting
      • Mantle Cell Lymphoma (MCL)
      • Nagoya-shi, Aichi, Japan
      • +11 more
      Apr 4, 2022

      Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic

      Withdrawn
      • CLL
      • +4 more
      • Treatment Free Observation
      • Basking Ridge, New Jersey
      • +8 more
      Mar 4, 2022

      Warm Autoimmune Hemolytic Anemia Trial in Beijing (Zanubrutinib)

      Not yet recruiting
      • Warm Autoimmune Hemolytic Anemia
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Jun 20, 2023

      Mantle Cell Lymphoma Trial in Germany, Italy, Switzerland (Ibrutinib, bortezomib)

      Terminated
      • Mantle Cell Lymphoma
      • Mainz, Germany
      • +18 more
      Feb 24, 2022

      Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

      Terminated
      Has Results
      • Small Lymphocytic Leukemia (SLL)
      • Chronic Lymphocytic Leukemia (CLL)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 15, 2022

      Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia Trial in New York (Ibrutinib,

      Recruiting
      • Waldenstrom Macroglobulinemia
      • +6 more
      • New York, New York
        Weill Cornell Medicine
      Dec 21, 2021

      Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

      Completed
      Has Results
      • Hepatitis
      • Safety and Tolerability
      • HEPLISAV-B
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 13, 2022

      Primary Central Nervous Lymphoma, Intraocular Lymphoma Trial in France (Ibrutinib)

      Completed
      • Primary Central Nervous Lymphoma
      • Intraocular Lymphoma
      • Clermont Ferrand, France
      • +9 more
      Apr 6, 2022

      CNS Lymphoma Trial in Beijing (Zanubrutinib)

      Recruiting
      • CNS Lymphoma
      • Beijing, Beijing, China
        Peking University People's Hospital
      Aug 1, 2022

      Waldenstrom Macroglobulinemia Trial in Tianjin (Zanubrutinib, Bendamustine and Rituximab)

      Recruiting
      • Waldenstrom Macroglobulinemia
      • Zanubrutinib, Bendamustine and Rituximab
      • Tianjin, Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Jun 13, 2023